| Name | Title | Contact Details |
|---|
Cellular Engineering Technologies is a Iowa City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Degraft-Johnson and Associates is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Secura Bio™ is a pharmaceutical company committed to giving patients access to innovative therapies. Headquartered in Henderson, Nevada, Secura Bio™ has operations in the U.S. and Offices in San Diego.
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.